Tonix Pharmaceuticals Holding (TNXP) Depreciation and Depletion (2011 - 2018)

Tonix Pharmaceuticals Holding's Depreciation and Depletion history runs 8 years deep, the most recent figure standing at $13000.0 for Q3 2018.

• On a quarterly basis, Depreciation and Depletion fell 18.75% year-over-year to $13000.0 in Q3 2018; TTM through Sep 2018 was $58000.0, a 100.18% increase from a year earlier, with the FY2017 full-year figure at $64000.0, down 51.88% from the prior year.
• Depreciation and Depletion slipped to $13000.0 in Q3 2018 per TNXP's latest filing, from $15000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $33.0 million in Q1 2016 and bottomed at -$32.9 million in Q4 2016.
• The 5-year median for Depreciation and Depletion is $16000.0 (2017), against an average of $19187.5.
• Biggest YoY gain for Depreciation and Depletion was 149900.0% in 2016; the steepest drop was 122070.37% in 2016.
• Year by year, Depreciation and Depletion stood at $21000.0 in 2014, then advanced by 28.57% to $27000.0 in 2015, then slumped by 122070.37% to -$32.9 million in 2016, then soared by 100.04% to $14000.0 in 2017, then decreased by 7.14% to $13000.0 in 2018.
• Per Business Quant, the three latest TNXP Depreciation and Depletion figures stand at $13000.0 (Q3 2018), $15000.0 (Q2 2018), and $14000.0 (Q4 2017).